Drug Profile

ABP 745

Alternative Names: ABP-745; Colchicine analogue - Atom Therapeutics

Latest Information Update: 01 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Atom Bioscience
Developer Atom Therapeutics
Class Anti-inflammatories; Antigouts; Cardiovascular therapies; Colchicum alkaloids; Small molecules
Mechanism of Action Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Gout
Preclinical Atherosclerosis; Inflammation

Most Recent Events

16 Dec 2025 US FDA approves IND application for ABP 745 in Atherosclerosis
16 Dec 2025 Pharmacodynamics data from a preclinical study in Atherosclerosis released by Atom Therapeutics
28 Oct 2025 Atom Therapeutics plans a phase II trial for Atherosclerosis in early 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com